• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch Health to Announce First-Quarter 2024 Results on May 2

    4/11/24 4:22:00 PM ET
    $BHC
    $NHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $BHC alert in real time by email

    LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

    Conference Call Details

    Date:

    Thursday, May 2, 2024

    Time:

    8:00 a.m. U.S. EDT

    Webcast:

    http://ir.bauschhealth.com/events-and-presentations

    A replay of the conference call will be available on the investor relations website.

    To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.

    About Bausch Health

    Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

    ###

    Investor Contact: Media Contact:
    Garen Sarafian Kevin Wiggins
    ir@bauschhealth.com corporate.communications@bauschhealth.com
    (877) 281-6642 (toll-free) (908) 541-3785

    SOURCE: Bausch Health Companies Inc.



    View the original press release on accesswire.com

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC
    $NHC

    CompanyDatePrice TargetRatingAnalyst
    Bausch Health Companies Inc.
    $BHC
    12/9/2025$8.00Equal Weight
    Barclays
    Bausch Health Companies Inc.
    $BHC
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    Bausch Health Companies Inc.
    $BHC
    7/10/2024$8.00Mkt Perform
    Raymond James
    Bausch Health Companies Inc.
    $BHC
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    Bausch Health Companies Inc.
    $BHC
    6/16/2023Outperform → Market Perform
    TD Cowen
    Bausch Health Companies Inc.
    $BHC
    7/29/2022Buy → Hold
    Truist
    Bausch Health Companies Inc.
    $BHC
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    Bausch Health Companies Inc.
    $BHC
    7/28/2022Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BHC
    $NHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

    Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education. "It is an honor to continue the AS

    3/26/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NHC Reports 2025 Year End Earnings

    National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues and grant income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%. The increase in net operating revenues for the 2025 year compared to the 2024 year was due to an 8.4% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Manor ("White Oak"). The White Oak operations consist of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four indep

    2/26/26 5:30:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    $BHC
    $NHC
    SEC Filings

    View All

    SEC Form DEF 14A filed by National HealthCare Corporation

    DEF 14A - NATIONAL HEALTHCARE CORP (0001047335) (Filer)

    4/2/26 4:31:31 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by National HealthCare Corporation

    SCHEDULE 13G/A - NATIONAL HEALTHCARE CORP (0001047335) (Subject)

    3/27/26 10:50:18 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by National HealthCare Corporation

    SCHEDULE 13G/A - NATIONAL HEALTHCARE CORP (0001047335) (Subject)

    3/12/26 5:09:02 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    $BHC
    $NHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Bausch Health with a new price target

    Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

    7/10/24 8:35:33 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Leung Sandra

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:30:13 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Paulson John

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:20:34 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wechsler Amy B

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:19:05 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Financials

    Live finance-specific insights

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NHC Reports 2025 Year End Earnings

    National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues and grant income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%. The increase in net operating revenues for the 2025 year compared to the 2024 year was due to an 8.4% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Manor ("White Oak"). The White Oak operations consist of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four indep

    2/26/26 5:30:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Leadership Updates

    Live Leadership Updates

    View All

    NHC Announces W. Andrew Adams Retirement from NHC Board of Directors

    National HealthCare Corporation (NYSE:NHC) announces the retirement of W. Andrew "Andy" Adams from the NHC Board of Directors effective after the annual meeting of shareholders on May 8, 2025. The son of NHC founder, Dr. Carl Adams, Andy Adams has had an unparalleled career of service and leadership at NHC. He originally joined NHC in 1972 as an Executive Officer. Andy then served as NHC's President from 1974 to 2004 and as Chief Executive Officer (CEO) from 1981 to 2004. Andy's service on the NHC Board of Directors began in 1974 where he also served as Chairman from 1994 to 2008. Andy had a significant impact on NHC. During his time in leadership, NHC's revenue grew to over $521 million i

    5/8/25 5:11:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Welcomes Two New Members to the Executive Leadership Team

    LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

    7/19/24 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by National HealthCare Corporation

    SC 13G - NATIONAL HEALTHCARE CORP (0001047335) (Subject)

    11/8/24 10:24:36 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

    SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

    8/19/24 5:48:41 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care